Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Anticancer Res ; 40(12): 6751-6763, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33288568

ABSTRACT

BACKGROUND/AIM: Chemoresistance is a major consequence of multicycle chemotherapy and can be attributed to constitutive activation of pro-survival signaling pathways. Nitric oxide is a ubiquitous signaling molecule which has been shown to inhibit several pathways involved with survival signaling in cancer cells. We have previously demonstrated the anti-tumor activity of a nitric oxide-donor, nitrosylcobalamin (NO-Cbl), mediated by increased expression of tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) and its receptors in human tumors. We also demonstrated that a functional Apo2L/TRAIL receptor is necessary for the induction of cell death by NO-Cbl and the Apo2L/TRAIL death receptor DR4 (TRAIL R1) is S-nitrosylated. The aim of the study was to examine the effects of nitric oxide (NO) on nuclear factor kappa B (NF-κB) and determine whether nitric oxide could sensitize drug-resistant melanomas to Apo2L/TRAIL via inhibition of NF-κB or inhibitor kappa B kinase (IKK). MATERIALS AND METHODS: Antiproliferative effects of NO-Cbl and Apo2L/TRAIL were assessed in malignant melanomas and non-tumorigenic melanocyte and fibroblast cell lines. Athymic nude mice bearing human melanoma A375 xenografts were treated with NO-Cbl and Apo2L/TRAIL. Apoptosis was measured by the TUNEL assay. The activation status of NF-κB was established by assaying luciferase reporter activity, the phosphorylation status of IκBα, and in vitro IKK activity. RESULTS: NO-Cbl sensitized Apo2L/TRAIL-resistant melanoma cell lines to growth inhibition by Apo2L/TRAIL, but had minimal effect on normal cell lines. NO-Cbl and Apo2L/TRAIL exerted synergistic anti-tumor activity against A375 xenografts. NO-Cbl suppressed Apo2L/TRAIL- and TNF-α-mediated activation of a transfected NF-κB-driven luciferase reporter. NO-Cbl inhibited IKK activation, characterized by decreased phosphorylation of IκBα. CONCLUSION: NO-Cbl treatment rendered Apo2L/TRAIL-resistant malignancies sensitive to the anti-tumor effects of Apo2L/TRAIL in vitro and in vivo. The use of nitric oxide to inhibit NF-κB and potentiate the effects of chemotherapeutic agents, such as Apo2L/TRAIL, represents a promising anti-cancer combination based on recent clinical investigations of anti-TRAIL antibodies for cancer treatment strategies.


Subject(s)
NF-kappa B/metabolism , Nitric Oxide/pharmacology , Signal Transduction , TNF-Related Apoptosis-Inducing Ligand/pharmacology , Animals , Apoptosis/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Humans , Male , Mice, Nude , NF-KappaB Inhibitor alpha/metabolism , Nitroso Compounds/pharmacology , Vitamin B 12/analogs & derivatives , Vitamin B 12/pharmacology , Xenograft Model Antitumor Assays
4.
Chromatographia ; 77(7-8): 571-589, 2014 Apr 01.
Article in English | MEDLINE | ID: mdl-24855323

ABSTRACT

Nitrosylcobalamin (NO-Cbl), a novel vitamin B12 analog and anti-tumor agent, functions as a biologic 'Trojan horse', utilizing the vitamin B12 transcobalamin II transport protein and cell surface receptor to specifically target cancer cells. a stability-indicating HPLC method was developed for the detection of NO-Cbl during forced degradation studies. This method utilized an ascentis® RP-amide (150 mm × 4.6 mm, 5 µm) column at 35 °C with a mobile phase (1.0 mL min-1) combining a gradient of methanol and an acetate buffer at pH 6.0. Detection wavelengths of 450 and 254 nm were used to detect corrin and non-corrin-based products, respectively. NO-Cbl, synthesized from hydroxocobalamin and pure nitric oxide gas, was subjected to degradative stress conditions including oxidation, hydrolysis and thermal and radiant energy challenge. The method was validated by assessing linearity, accuracy, precision, detection and quantitation limits and robustness. The method was applied successfully for purity assessment of synthesized NO-Cbl and for the determination of NO-Cbl during kinetic studies in aqueous solution and in solid-state degradation assessments. This HPLC method is suitable for the separation of cobalamins in aqueous and methanolic solutions, for routine detection of NO-Cbl and for purity assessment of synthesized NO-Cbl. additionally, this method has potential application in identification and monitoring of diseases involving altered nitric oxide homeostasis where vitamin B12 therapy is utilized to scavenge excess nitric oxide, subsequently resulting in the in vivo production of NO-Cbl.

5.
Trustee ; 66(7): 13-4, 19-20, 1, 2013.
Article in English | MEDLINE | ID: mdl-23926861

ABSTRACT

The ability to preserve local services after a merger comes from the contract, not the number of board seats.


Subject(s)
Governing Board/organization & administration , Health Facility Merger , Organizational Objectives , Contract Services , Hospitals, Community , Humans , Leadership , Negotiating
6.
Trustee ; 65(10): 13-4, 19-20, 1, 2012.
Article in English | MEDLINE | ID: mdl-23259224

ABSTRACT

A full-fledged merger isn't the only solution for struggling hospitals.


Subject(s)
Decision Making, Organizational , Health Facility Merger , Professional Role , Trustees , United States
7.
J Biol Chem ; 284(45): 30825-35, 2009 Nov 06.
Article in English | MEDLINE | ID: mdl-19726691

ABSTRACT

High density lipoprotein (HDL) is the major atheroprotective particle in plasma. Recent studies demonstrate that myeloperoxidase (MPO) binds to HDL in vivo, selectively targeting apolipoprotein A1 (apoA1) of HDL for oxidative modification and concurrent loss in cholesterol efflux and lecithin cholesterol acyl transferase activating activities, generating a "dysfunctional HDL" particle. We now show that (patho)physiologically relevant levels of MPO-catalyzed oxidation result in loss of non-cholesterol efflux activities of HDL including anti-apoptotic and anti-inflammatory functions. One mechanism responsible is shown to involve the loss of modified HDL binding to the HDL receptor, scavenger receptor B1, and concurrent acquisition of saturable and specific binding to a novel unknown receptor independent of scavenger receptors CD36 and SR-A1. HDL modification by MPO is further shown to confer pro-inflammatory gain of function activities as monitored by NF-kappaB activation and surface vascular cell adhesion molecule levels on aortic endothelial cells exposed to MPO-oxidized HDL. The loss of non-cholesterol efflux activities and the gain of pro-inflammatory functions requires modification of the entire particle and can be recapitulated by oxidation of reconstituted HDL particles comprised of apoA1 and nonoxidizable phosphatidylcholine species. Multiple site-directed mutagenesis studies of apoA1 suggest that the pro-inflammatory activity of MPO-modified HDL does not involve methionine, tyrosine, or tryptophan, oxidant-sensitive residues previously mapped as sites of apoA1 oxidation within human atheroma. Thus, MPO-catalyzed oxidation of HDL results not only in the loss of classic atheroprotective reverse cholesterol transport activities of the lipoprotein but also both the loss of non-cholesterol efflux related activities and the gain of pro-inflammatory functions.


Subject(s)
Inflammation Mediators/immunology , Lipoproteins, HDL/immunology , Peroxidase/metabolism , Protein Processing, Post-Translational , Animals , Apolipoprotein A-I/genetics , Apolipoprotein A-I/immunology , Cell Line , Humans , Inflammation Mediators/metabolism , Lipoproteins, HDL/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Oxidation-Reduction , Peroxidase/genetics , Protein Binding , Receptors, Lipoprotein/metabolism
8.
PLoS One ; 2(12): e1313, 2007 Dec 12.
Article in English | MEDLINE | ID: mdl-18074035

ABSTRACT

BACKGROUND: Nitrosylcobalamin (NO-Cbl) is a chemotherapeutic pro-drug derived from vitamin B12 that preferentially delivers nitric oxide (NO) to tumor cells, based upon increased receptor expression. NO-Cbl induces Apo2L/TRAIL-mediated apoptosis and inhibits survival signaling in a variety of malignant cell lines. Chemotherapeutic agents often simultaneously induce an apoptotic signal and activation of NF-kappaB, which has the undesired effect of promoting cell survival. The specific aims of this study were to 1) measure the anti-tumor effects of NO-Cbl alone and in combination with conventional chemotherapeutic agents, and to 2) examine the mechanism of action of NO-Cbl as a single agent and in combination therapy. METHODOLOGY: Using anti-proliferative assays, electrophoretic mobility shift assay (EMSA), immunoblot analysis and kinase assays, we demonstrate an increase in the effectiveness of chemotherapeutic agents in combination with NO-Cbl as a result of suppressed NF-kappaB activation. RESULTS: Eighteen chemotherapeutic agents were tested in combination with NO-Cbl, in thirteen malignant cell lines, resulting in a synergistic anti-proliferative effect in 78% of the combinations tested. NO-Cbl pre-treatment resulted in decreased NF-kappaB DNA binding activity, inhibition of IkappaB kinase (IKK) enzymatic activity, decreased AKT activation, increased caspase-8 and PARP cleavage, and decreased cellular XIAP protein levels. CONCLUSION: The use of NO-Cbl to inhibit survival signaling may enhance drug efficacy by preventing concomitant activation of NF-kappaB or AKT.


Subject(s)
Antineoplastic Agents/pharmacology , Nitroso Compounds/pharmacology , Signal Transduction/drug effects , Vitamin B 12/analogs & derivatives , Apolipoproteins/physiology , Apoptosis/drug effects , Apoptosis/physiology , Cell Line, Tumor , Electrophoretic Mobility Shift Assay , Enzyme Activation , Humans , I-kappa B Kinase/metabolism , NF-kappa B/metabolism , Proto-Oncogene Proteins c-akt/metabolism , TNF-Related Apoptosis-Inducing Ligand/physiology , Vitamin B 12/pharmacology , X-Linked Inhibitor of Apoptosis Protein/metabolism
9.
J Biol Chem ; 282(21): 15349-56, 2007 05 25.
Article in English | MEDLINE | ID: mdl-17379600

ABSTRACT

We previously showed that inositol hexakisphosphate kinase 2 (IHPK2) functions as a growth-suppressive and apoptosis-enhancing kinase during cell stress. Overexpression of IHPK2 sensitized ovarian carcinoma cell lines to the growth-suppressive and apoptotic effects of interferon beta (IFN-beta), IFN-alpha2, and gamma-irradiation. Expression of a kinase-dead mutant abrogated 50% of the apoptosis induced by IFN-beta. Because the kinase-dead mutant retained significant response to cell stressors, we hypothesized that a portion of the death-promoting function of IHPK2 was independent of its kinase activity. We now demonstrate that IHPK2 binds to tumor necrosis factor (TNF) receptor-associated factor (TRAF) 2 and interferes with phosphorylation of transforming growth factor beta-activated kinase 1 (TAK1), thereby inhibiting NF-kappaB signaling. IHPK2 contains two sites required for TRAF2 binding, Ser-347 and Ser-359. Compared with wild type IHPK2-transfected cells, cells expressing S347A and S359A mutations displayed 3.5-fold greater TAK1 activation following TNF-alpha. This mutant demonstrated a 6-10-fold increase in NF-kappaB DNA binding following TNF-alpha compared with wild type IHPK2-expressing cells in which NF-kappaB DNA binding was inhibited. Cells transfected with wild type IHPK2 or IHPK2 mutants that lacked S347A and S359A mutations displayed enhanced terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling staining following TNF-alpha. We believe that IHPK2-TRAF2 binding leads to attenuation of TAK1- and NF-kappaB-mediated signaling and is partially responsible for the apoptotic activity of IHPK2.


Subject(s)
Apoptosis , MAP Kinase Kinase Kinases/metabolism , MAP Kinase Signaling System , Phosphotransferases (Phosphate Group Acceptor)/metabolism , TNF Receptor-Associated Factor 2/metabolism , Amino Acid Substitution , Animals , Apoptosis/drug effects , Apoptosis/genetics , Apoptosis/radiation effects , Cell Line, Tumor , Gamma Rays , Gene Expression , Humans , Interferon-alpha/pharmacology , Interferon-beta/pharmacology , MAP Kinase Kinase Kinases/genetics , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/genetics , MAP Kinase Signaling System/radiation effects , Mice , Mutation, Missense , NF-kappa B/metabolism , Phosphotransferases (Phosphate Group Acceptor)/genetics , Protein Binding/genetics , TNF Receptor-Associated Factor 2/genetics
10.
BMC Microbiol ; 4: 33, 2004 Aug 23.
Article in English | MEDLINE | ID: mdl-15324458

ABSTRACT

BACKGROUND: Infection of intestinal epithelial cells by pathogenic Salmonella leads to activation of signaling cascades that ultimately initiate the proinflammatory gene program. The transcription factor NF-kappa B is a key regulator/activator of this gene program and is potently activated. We explored the mechanism by which Salmonella activates NF-kappa B during infection of cultured intestinal epithelial cells and found that flagellin produced by the bacteria and contained on them leads to NF-kappa B activation in all the cells; invasion of cells by the bacteria is not required to activate NF-kappa B. RESULTS: Purified flagellin activated the mitogen activated protein kinase (MAPK), stress-activated protein kinase (SAPK) and I kappa B kinase (IKK) signaling pathways that lead to expression of the proinflammatory gene program in a temporal fashion nearly identical to that of infection of intestinal epithelial cells by Salmonella. Flagellin expression was required for Salmonella invasion of host cells and it activated NF-kappa B via toll-like receptor 5 (TLR5). Surprisingly, a number of cell lines found to be unresponsive to flagellin express TLR5 and expression of exogenous TLR5 in these cells induces NF-kappa B activity in response to flagellin challenge although not robustly. Conversely, overexpression of dominant-negative TLR5 alleles only partially blocks NF-kappa B activation by flagellin. These observations are consistent with the possibility of either a very stable TLR5 signaling complex, the existence of a low abundance flagellin co-receptor or required adapter, or both. CONCLUSION: These collective results provide the evidence that flagellin acts as the main determinant of Salmonella mediated NF-kappa B and proinflammatory signaling and gene activation by this flagellated pathogen. In addition, expression of the fli C gene appears to play an important role in the proper functioning of the TTSS since mutants that fail to express fli C are defective in expressing a subset of Sip proteins and fail to invade host cells. Flagellin added in trans cannot restore the ability of the fli C mutant bacteria to invade intestinal epithelial cells. Lastly, TLR5 expression in weak and non-responding cells indicates that additional factors may be required for efficient signal propagation in response to flagellin recognition.


Subject(s)
Flagellin/immunology , Membrane Glycoproteins/physiology , NF-kappa B/physiology , Receptors, Cell Surface/physiology , Signal Transduction/physiology , Adaptor Proteins, Signal Transducing , Antigens, Differentiation/metabolism , Bacterial Proteins/immunology , Bacterial Proteins/metabolism , Cell Line, Tumor , Cells, Cultured , Central Nervous System Neoplasms/genetics , Central Nervous System Neoplasms/pathology , DNA/metabolism , Enzyme Activation/physiology , Epithelial Cells/enzymology , Epithelial Cells/microbiology , Flagellin/metabolism , Glioblastoma/genetics , Glioblastoma/pathology , HT29 Cells/chemistry , HT29 Cells/metabolism , HeLa Cells/chemistry , HeLa Cells/metabolism , Humans , I-kappa B Kinase , Inflammation/genetics , Intestines/microbiology , Intestines/pathology , Kidney/chemistry , Kidney/cytology , Kidney/embryology , Kidney/metabolism , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Mitogen-Activated Protein Kinase Kinases/metabolism , Mitogen-Activated Protein Kinases/metabolism , Myeloid Differentiation Factor 88 , NF-kappa B/metabolism , Protein Binding , Protein Serine-Threonine Kinases/metabolism , Receptors, Immunologic/metabolism , Salmonella/immunology , Salmonella Infections/pathology , Solubility , Toll-Like Receptor 5 , Toll-Like Receptors
11.
J Biol Chem ; 278(41): 39461-9, 2003 Oct 10.
Article in English | MEDLINE | ID: mdl-12881518

ABSTRACT

We have previously demonstrated the anti-tumor activity of nitrosylcobalamin (NO-Cbl), an analog of vitamin B12 that delivers nitric oxide (NO) and increases the expression of tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) and its receptors in human tumors. The specific aim of this study was to examine whether NO-Cbl could sensitize drug-resistant melanomas to Apo2L/TRAIL. Antiproliferative effects of NO-Cbl and Apo2L/TRAIL were assessed in malignant melanomas and non-tumorigenic melanocyte and fibroblast cell lines. Athymic nude mice bearing human melanoma A375 xenografts were treated with NO-Cbl and Apo2L/TRAIL. Apoptosis was measured by TUNEL and confirmed by examining levels and activity of key mediators of apoptosis. The activation status of NF-kappa B was established by assaying DNA binding, luciferase reporter activity, the phosphorylation status of I kappa B alpha, and in vitro IKK activity. NO-Cbl sensitized Apo2L/TRAIL-resistant melanoma cell lines to growth inhibition by Apo2L/TRAIL but had minimal effect on normal cell lines. NO-Cbl and Apo2L/TRAIL exerted synergistic anti-tumor activity against A375 xenografts. Treatment with NO-Cbl followed by Apo2L/TRAIL induced apoptosis in Apo2L/TRAIL-resistant tumor cells, characterized by cleavage of caspase-3, caspase-8, and PARP. NO-Cbl inhibited IKK activation, characterized by decreased phosphorylation of I kappa B alpha and inhibition of NF-kappa B DNA binding activity. NO-Cbl suppressed Apo2L/TRAIL- and TNF-alpha-mediated activation of a transfected NF-kappa B-driven luciferase reporter. XIAP, an inhibitor of apoptosis, was inactivated by NO-Cbl. NO-Cbl treatment rendered Apo2L/TRAIL-resistant malignancies sensitive to the anti-tumor effects of Apo2L/TRAIL in vitro and in vivo. The use of NO-Cbl and Apo2L/TRAIL capitalizes on the tumor-specific properties of both agents and represents a promising anti-cancer combination.


Subject(s)
Melanoma, Experimental/drug therapy , Melanoma, Experimental/metabolism , Membrane Glycoproteins/pharmacology , NF-kappa B/metabolism , Nitroso Compounds/pharmacology , Tumor Necrosis Factor-alpha/pharmacology , Vitamin B 12/analogs & derivatives , Vitamin B 12/pharmacology , Animals , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Apoptosis Regulatory Proteins , Base Sequence , Binding Sites/genetics , Cell Line , Cell Line, Tumor , Cell Survival/drug effects , DNA, Neoplasm/genetics , DNA, Neoplasm/metabolism , Drug Resistance, Neoplasm , Enzyme Inhibitors/pharmacology , Humans , I-kappa B Kinase , Melanoma, Experimental/pathology , Mice , Mice, Nude , Neoplasm Transplantation , Protein Serine-Threonine Kinases/antagonists & inhibitors , Signal Transduction/drug effects , TNF-Related Apoptosis-Inducing Ligand , Transplantation, Heterologous
12.
J Appl Physiol (1985) ; 93(6): 2038-43, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12391056

ABSTRACT

Quantitations of exhaled nitric oxide (NO) and carbon monoxide (CO) have been proposed as noninvasive markers of airway inflammation. We hypothesized that exhaled CO is increased in individuals with alpha(1)-antitrypsin (AT) deficiency, who have lung inflammation and injury related to oxidative and proteolytic processes. Nineteen individuals with alpha(1)-AT deficiency, 22 healthy controls, and 12 patients with non-alpha(1)-AT-deficient chronic obstructive pulmonary disease (COPD) had NO, CO, CO(2), and O(2) measured in exhaled breath. Individuals with alpha(1)-AT deficiency had lower levels of NO and CO than control or COPD individuals. Alpha(1)-AT-deficient and COPD patients had lower exhaled CO(2) than controls, although only alpha(1)-AT-deficient patients had higher exhaled O(2) than healthy controls. NO was correlated inversely with exhaled O(2) and directly with exhaled CO(2), supporting a role for NO in regulation of gas exchange. Exhaled gases were not significantly related to corticosteroid use or lung function. Demonstration of lower than normal CO and NO levels may be useful as an additional noninvasive method to evaluate alpha(1)-AT deficiency in individuals with a severe, early onset of obstructive lung disease.


Subject(s)
Carbon Monoxide/analysis , Nitric Oxide/analysis , alpha 1-Antitrypsin Deficiency/diagnosis , alpha 1-Antitrypsin Deficiency/metabolism , Administration, Inhalation , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Biomarkers , Breath Tests , Carbon Dioxide/analysis , Female , Humans , Male , Middle Aged , Oxygen/analysis , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/drug therapy , Pulmonary Disease, Chronic Obstructive/metabolism , alpha 1-Antitrypsin Deficiency/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...